Segment Disclosures - Schedule of Selected Financial Information (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 |
Jun. 30, 2026 |
Mar. 31, 2026 |
Sep. 30, 2025 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
|
| Segment Reporting [Line Items] | ||||||||
| Total revenues | $ 1,604 | $ 1,666 | $ 3,844 | $ 1,718 | ||||
| Less: | ||||||||
| Cost of sales | 2,669 | 1,577 | 9,556 | 1,577 | ||||
| Research and development | ||||||||
| Total research and development | 39,221 | 27,884 | 137,608 | 86,683 | ||||
| General and administrative | 22,963 | 23,334 | 72,719 | 55,532 | ||||
| Total costs and operating expenses | 64,853 | 52,795 | 219,883 | 143,792 | ||||
| Loss from operations | (63,249) | (51,129) | (216,039) | (142,074) | ||||
| Other income, net | 6,358 | 7,321 | 19,890 | 22,388 | ||||
| Net loss | (56,891) | $ (79,056) | $ (60,202) | (43,808) | $ (41,426) | $ (34,452) | (196,149) | (119,686) |
| Commercial and development revenue | ||||||||
| Segment Reporting [Line Items] | ||||||||
| Total revenues | 1,604 | 1,508 | 3,820 | 1,508 | ||||
| License and collaboration revenue | ||||||||
| Segment Reporting [Line Items] | ||||||||
| Total revenues | 0 | 158 | 24 | 210 | ||||
| Reportable Segment | ||||||||
| Segment Reporting [Line Items] | ||||||||
| Total revenues | 1,604 | 1,666 | 3,844 | 1,718 | ||||
| Less: | ||||||||
| Cost of sales | 2,669 | 1,577 | 9,556 | 1,577 | ||||
| Research and development | ||||||||
| Clinical and manufacturing | 31,940 | 23,381 | 122,012 | 72,818 | ||||
| Other research and development | 7,281 | 4,503 | 15,596 | 13,865 | ||||
| Total research and development | 39,221 | 27,884 | 137,608 | 86,683 | ||||
| General and administrative | 22,963 | 23,334 | 72,719 | 55,532 | ||||
| Total costs and operating expenses | 64,853 | 52,795 | 219,883 | 143,792 | ||||
| Loss from operations | (63,249) | (51,129) | (216,039) | (142,074) | ||||
| Other income, net | 6,358 | 7,321 | 19,890 | 22,388 | ||||
| Net loss | (56,891) | (43,808) | (196,149) | (119,686) | ||||
| Reportable Segment | Commercial and development revenue | ||||||||
| Segment Reporting [Line Items] | ||||||||
| Total revenues | 1,604 | 1,508 | 3,820 | 1,508 | ||||
| Reportable Segment | License and collaboration revenue | ||||||||
| Segment Reporting [Line Items] | ||||||||
| Total revenues | $ 0 | $ 158 | $ 24 | $ 210 | ||||
| X | ||||||||||
- Definition Clinical And Manufacturing Expense No definition available.
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|